IPM 014A
Status:Completed
Phase:II, I
Principal Investigator(s):Dr Annalene Nel
Objective:The purpose of this study is to determine whether dapivirine gel 4759 is safe for daily use by healthy women in Kenya, Malawi, Rwanda, South Africa and Tanzania.
Prevention Option(s):Microbicides
Study Design:Randomized
Arms and Assigned Interventions
Descriptiondosage: 1.25mg dapivirine/day
frequency: once daily
duration: 6 weeks
Mode of DeliveryGel
ARMsExperimental
Official Code:
NCT00917891
Trial Sponsors:
IPM
Start Date
End Date
September 1, 2009
September 1, 2011
Enrollment:280
Age range:
18 Years ↔
40 Years
Population:Cisgender Women